Celcuity Stock Sees Significant Surge
Celcuity Inc. (NASDAQ: CELC) has made headlines with a notable jump in stock value, driven by encouraging topline results from a recent clinical trial. The VIKTORIA-1 trial, which focused on patients with hormone receptor-positive, HER2-negative advanced breast cancer, showcased the effectiveness of gedatolisib in combination with fulvestrant, both with and without palbociclib.
Details of the VIKTORIA-1 Trial
The Phase 3 VIKTORIA-1 trial enrolled adult participants suffering from locally advanced or metastatic breast cancer. These patients had previously experienced disease progression following treatment with a CDK4/6 inhibitor, combined with an aromatase inhibitor. This trial specifically analyzed patients with the PIK3CA wild-type gene to assess the efficacy of the gedatolisib combination therapy.
Statistical Significance in Findings
The results from the trial revealed substantial and clinically meaningful improvements in progression-free survival (PFS). Patients receiving the gedatolisib triplet therapy displayed a remarkable 76% reduction in the risk of disease progression or death compared to those treated with fulvestrant alone. The median PFS for the gedatolisib group reached 9.3 months, compared to just 2.0 months for the fulvestrant group, marking an impressive improvement.
Evaluating the Gedatolisib Doublet
Notably, the gedatolisib doublet treatment also yielded significant results. This approach produced a 67% reduction in the risk of disease complications compared to fulvestrant. The median PFS for participants receiving this therapy was recorded at 7.4 months, showcasing an incremental improvement of 5.4 months over the fulvestrant group.
Setting New Milestones in Drug Development
The topline data from this trial has established several new benchmarks in the ongoing journey of drug development for advanced breast cancer. The favorable hazard ratios presented by the gedatolisib triplet and doublet treatments represent a historic finding for patients facing HR+/HER2- forms of the disease.
Next Steps for Celcuity Inc.
Looking forward, Celcuity plans to present comprehensive findings from the VIKTORIA-1 trial at an upcoming medical conference. Furthermore, the company is aiming to submit a New Drug Application (NDA) for gedatolisib to the U.S. Food and Drug Administration by the fourth quarter of 2025, highlighting their commitment to advancing this innovative treatment.
Ongoing Trials
In addition to the VIKTORIA-1 study, Celcuity is actively conducting the VIKTORIA-2 Phase 3 trial, which is set to assess the combination therapy of gedatolisib and fulvestrant along with a CDK4/6 inhibitor versus fulvestrant with a CDK4/6 inhibitor. This ongoing research aims to support patients exhibiting treatment resistance in endocrine therapies.
New Patent Acquisition
Recently, in July, Celcuity secured a patent covering the clinical dosing regimen for gedatolisib, extending its exclusivity until 2042. This move not only underscores the innovative efforts of the company but also positions it strategically within the oncology market.
Price Action of Celcuity Stock
As a direct response to these groundbreaking trial results, shares of CELC surged by over 222%, reflecting investor confidence and anticipation surrounding Celcuity's future developments in breast cancer treatment.
Frequently Asked Questions
What is the latest on Celcuity's stock performance?
Celcuity Inc. (NASDAQ: CELC) recently saw its stock price increase significantly due to promising clinical trial results.
What were the main findings of the VIKTORIA-1 trial?
The trial demonstrated significant improvement in progression-free survival for patients treated with gedatolisib combined with fulvestrant, showing a 76% reduction in the risk of disease progression or death.
When does Celcuity plan to submit its NDA?
Celcuity aims to submit a New Drug Application for gedatolisib to the FDA in the fourth quarter of 2025.
What is the significance of the recent patent acquisition?
The new patent protects the clinical dosing regimen for gedatolisib, extending market exclusivity until 2042, which allows Celcuity to solidify its position in the oncology market.
What future trials is Celcuity conducting?
Celcuity is currently conducting the VIKTORIA-2 trial to evaluate the efficacy of gedatolisib combined with fulvestrant and a CDK4/6 inhibitor against standard treatments for patients resistant to endocrine therapy.
